Our faculty will now address the most commonly asked questions.

Hi, my name is James Galvin, and I'm a professor of neurology at the University of Miami Miller School of Medicine in Boca Raton, Florida.

In this activity, we'll explore the use of anti-amyloid therapies to treat patients with early Alzheimer's disease with a focus on long-term evidence.

In this first session, I'll discuss some of the latest advances in dosing and administration and review long-term efficacy clinical data.

Now, here we can see there are two approved therapies, the anti-amyloid immunotherapies for early-stage Alzheimer's disease.

These are monoclonal antibodies, and they've been approved by the FDA for the treatment of Alzheimer's disease.

They're indicated for patients with mild cognitive impairment or mild dementia stage of the disease.